


## (S)-Viloxazine-d<sub>5</sub> hydrochloride

<b>Cat. No.:</b>	HY-125784BS
<b>CAS No.:</b>	1246816-39-6
<b>Molecular Formula:</b>	C <sub>13</sub> H <sub>15</sub> D <sub>5</sub> ClNO <sub>3</sub>
<b>Molecular Weight:</b>	278.79
<b>Target:</b>	Isotope-Labeled Compounds
<b>Pathway:</b>	Others
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (358.69 mM; ultrasonic and heat to 80°C)

Concentration	Mass			
	1 mg	5 mg	10 mg	
1 mM	3.5869 mL	17.9346 mL	35.8693 mL	
5 mM	0.7174 mL	3.5869 mL	7.1739 mL	
10 mM	0.3587 mL	1.7935 mL	3.5869 mL	

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

(S)-Viloxazine-d<sub>5</sub> (hydrochloride) is the deuterium labeled (S)-Viloxazine hydrochloride[1].

#### In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA